As part of the ongoing multinational SENTRY antimicrobial resistance surveillance program, a total of 1,047 respiratory tract isolates of Streptococcus pneumoniae, 845 from 27 United States medical centers and 202 from seven Canadian institutions, were collected between February and June 1997 and characterized in a central laboratory. In the United States, the overall percentages of penicillin-intermediate strains and strains with high-level resistance to penicillin were 27.8% and 16.0%, respectively. In Canada, these values were 21.8% and 8.4%, respectively. Among the 31 centers in the United States and Canada that contributed at least 19 isolates, the combined rate of intermediate plus resistant strains varied between 24.0% and 67.8%. The in vitro activity of 19 other antimicrobials was assessed against all study isolates. Overall rates of resistance among selected agents in the United States and Canada, respectively, were as follows: amoxicillin, 18.1% and 10.5%; cefaclor, 38.3% and 26.2%; cefuroxime, 19.5% and 12.9%; cefpodoxime, 18.6% and 11.4%; cefepime, 8.2% and 4.5%; cefotaxime, 4.0% and 3.0%; macrolides (i.e., erythromycin, azithromycin, and clarithromycin), 11.7% -14.3% and 5.0% -7.4%; clindamycin, 3.5% and 3.5%; chloramphenicol, 3.9% and 4.0%; tetracycline, 10.2% and 10.9%; and trimethoprim-sulfamethoxazole, 19.8% and 15.8%.
Penicillin-resistant Streptococcus pneumoniae (PRSP) was
it had reached 24.6% [9] . During the latter part of 1995, penicillin resistance was noted in 27.2% of clinical isolates of S. pneumoniae described for the first time in 1964 [1] . Two levels of penicillin [10] . The most recent systematic nationwide surveillance study resistance exist in pneumococci: intermediate (MICs, in the United States revealed an overall rate of penicillin resistance mg/mL) and high level (MICs, §2 mg/mL) [2, 3] . Since its of 34.6% during 1996 [11] . original description, PRSP has become a major problem in Similarly, in Canada, PRSP remained uncommon during the many parts of the world [4] .
1980s [12, 13] . However, a 1994 -1995 multicenter national surveillance study noted an overall resistance rate of 11.7% See editorial response by Mufson on pages 771 -3. among S. pneumoniae isolates in Canada [14] . The principal mechanism of penicillin resistance is the proUntil the early 1990s, however, PRSP remained uncommon in duction of altered penicillin-binding proteins [15, 16] . With the United States [5, 6] . The latest large multicenter surveillance S. pneumoniae, all b-lactam antimicrobials bind to the same study conducted in this country during the 1980s revealed an or related penicillin-binding proteins to manifest their antimioverall rate of penicillin resistance of only 3.8%, with the vast crobial effect [17, 18] . As a result, penicillin resistance of majority of nonsusceptible isolates having only intermediate levels S. pneumoniae leads in all cases to at least some degree of of resistance [6] . By 1992, however, the rate of penicillin resiscross-resistance to penicillin congeners, cephalosporins, b-lactance had jumped to 17.8% [7] . Since then, four large multicenter tam/b-lactamase-inhibitor combinations, and carbapenems surveillance studies have been performed in the United States [19 -22] . It is not surprising, therefore, that as penicillin resis- [8] [9] [10] [11] . These studies have documented a steady increase in the tance of S. pneumoniae has emerged as a problem, resistance prevalence of PRSP in the United States during the past 5 years.
has become apparent to other b-lactams, including even exIn 1993, the overall resistance rate was 22.3% [8] ; by [1994] [1995] tended-spectrum third-generation cephalosporins [8 -10] NOTE. R Å resistant; S Å susceptible. Breakpoints (mg/mL) used to define susceptibility categories are those recommended for use by the National Committee for Clinical Laboratory Standards (NCCLS) [3] , except in the case of cefadroxil, cefaclor, cefixime, and cefpodoxime, for which no breakpoints have been developed. With all four of these cephalosporins, the following breakpoints were applied: 0.5 mg/mL, susceptible; 1 mg/mL, intermediate; and 2 mg/mL, resistant.
* Interpretive breakpoints of this drug combination for S. pneumoniae have not been developed; the value listed in the ''S (%)'' columns is the modal MIC value.
/ 9c57$$oc40 09-16-98 11:23:59 cidas UC: CID [14] and indicates that the gap between pneumococcal penicillin-resistance rates in the United States was true for TMP-SMZ and the three macrolides examined in this study: erythromycin, azithromycin, and clarithromycin. Rates and Canada is narrowing.
Rates of resistance to other b-lactams are also clearly inof resistance to clindamycin, chloramphenicol, tetracycline, rifampin, and quinupristin/dalfopristin were comparable in both councreasing. These include amoxicillin, amoxicillin/clavulanate, and the seven cephalosporins examined in this study. Among tries. All isolates of S. pneumoniae in both the United States and Canada were susceptible to vancomycin; the vancomycin MIC 90 the cephalosporins, cefadroxil had limited activity, even against penicillin-susceptible strains of S. pneumoniae. Among the revalues were 0.5 mg/mL in both countries.
When comparisons were based on percentages of susceptible, maining six agents in this group, there appeared to be three general groupings based on antipneumococcal activity. intermediate, and resistant strains, amoxicillin and amoxicillin/ clavulanate were significantly more active than penicillin (table (1) Cefaclor and cefixime had variable activity against penicillin-susceptible isolates of S. pneumoniae, marginal activity 1). Both of these agents were Ç1.5-fold more active than penicillin, on the basis of potency. The rank order of activity of cephaloagainst intermediate strains, and essentially no activity against resistant isolates. (2) Cefuroxime and cefpodoxime had nearly sporins, based on both comparisons of MICs and percentages of susceptible, intermediate, and resistant strains, was as follows:
uniform activity against penicillin-susceptible organisms, variable activity against intermediate isolates, and essentially no cefotaxime § cefepime ú cefpodoxime Å cefuroxime ú cefixime § cefaclor ú cefadroxil. Although there were subtle differactivity against highly penicillin-resistant organisms. (3) Cefepime and cefotaxime had nearly uniform activity against peniences in the activity of macrolides against S. pneumoniae when comparisons were based on MICs (clarithromycin § erythromycillin-susceptible isolates, considerable activity against intermediate strains, and marginal activity against resistant cin § azithromycin), comparisons based on percentages of susceptible, intermediate, and resistant strains indicated essential organisms. This stratification of cephalosporin activity on the basis of equivalence among these structurally similar compounds.
High rates of TMP-SMZ resistance were noted in both the level of penicillin resistance of S. pneumoniae isolates has been well-documented in the literature and is explained by common United States (19.8%) and Canada (15.8%). Slightly lower rates of tetracycline resistance were observed (10.2% and 10.9%, penicillin-binding-protein targets of action [17 -22] . It is not surprising, therefore, that as rates of penicillin resistance have respectively). Chloramphenicol (3.9% overall resistance) and clindamycin (3.6% overall resistance) were two of the most increased, so also have rates of cephalosporin resistance. Among the cephalosporins tested in this surveillance study, active agents tested; rifampin was nearly uniformly active, and vancomycin resistance was not observed. Interpretive criteria only cefuroxime, cefpodoxime, cefepime, and cefotaxime retain sufficient activity to be considered for empirical managehave not been established for MICs of the combination quinupristin/dalfopristin for S. pneumoniae. However, a very narrow ment of infections known or suspected to be caused by S. pneumoniae. The results of cefotaxime MIC determinations range of MICs was noted with this combination: for no organism was the MIC ú4 mg/mL, and for 98.6% of test strains in may also be considered indicative of the activity of ceftriaxone, as these two agents are essentially comparable against S. pneuthe United States and Canada the quinupristin/dalfopristin MIC was £1 mg/mL. moniae.
As was the case with the cephalosporins, the activity of As seen in table 3, there was a clear relationship between penicillin activity and the activity of other b-lactam agents, amoxicillin and amoxicillin/clavulanate, assessed via MIC values or by percentages of resistant strains, also varied according macrolides, clindamycin, tetracycline, and TMP-SMZ. In all cases, resistance to these agents was more common among to the level of penicillin resistance. This has previously been described in the literature [20] . Of interest were comparisons penicillin-intermediate strains than among penicillin-susceptible strains, and it was most common among highly penicillinof absolute rates of resistance between these two agents and penicillin. Rates of amoxicillin and amoxicillin/clavulanate reresistant organisms. It is noteworthy that resistance to cefuroxime, cefotaxime, and cefepime (i.e., MICs of §2 mg/mL) was sistance were essentially equivalent and generally less than one-half the rate of resistance to penicillin. This is clearly the never observed among penicillin-susceptible isolates.
result of the different MIC breakpoints that have been assigned to these agents [3] .
Discussion
The actual MICs for individual test strains were nearly identical; to wit, penicillin, amoxicillin, and amoxicillin/clavulanate The results of this surveillance study demonstrated a continuing increase in the prevalence of penicillin resistance among have equivalent antipneumococcal activity on a per-weight basis. The lower breakpoints applied to penicillin are consistent respiratory tract isolates of S. pneumoniae in the United States. The overall rate of penicillin resistance was 43.8%. In addition, with the lower serum levels that are typically achieved with this agent. That amoxicillin or amoxicillin/clavulanate is actuwe noted that 30.2% of isolates from Canada were nonsusceptible to penicillin. This also represents a conspicuous increase ally more efficacious because of greater bioavailability than / 9c57$$oc40 09-16-98 11:23:59 cidas UC: CID The largest amount of information regarding this issue concerns b-lactam antimicrobial agents. Clearly, in patients with pneumoerythromycin, which in turn was consistently one doublingdilution more active than azithromycin. Again, because of difcoccal meningitis, treatment with penicillin or an extended-spectrum third-generation cephalosporin such as cefotaxime or ceftriferent MIC interpretive breakpoints [3] , when comparisons were made between these agents on the basis of resistance axone is typically associated with therapeutic failure, often manifesting as late relapse, when infection is caused by either categories, there were essentially no differences (i.e., isolates resistant, intermediate, or susceptible to one agent were categointermediate or highly resistant strains [24] [25] [26] [27] . The same appears to be the case in acute otitis media treated with cefuroxime axetil, rized in the same way against the other two agents).
As was true with the macrolides, overall rates of resistance when infection is caused by S. pneumoniae that is intermediate or resistant to cefuroxime [28] . to clindamycin (3.7%), tetracycline (10.2%), chloramphenicol (3.9%), and TMP-SMZ (19.8%) also appear to have changed In pneumococcal pneumonia, there is not as clear a relationship between in vitro activity and outcome. Indeed, in one large little during the past 3 years in the United States [9] . It is interesting that rates of resistance to clindamycin, tetracycline, study, mortality rates were no different between patients with pneumonia due to penicillin-susceptible vs. intermediate or chloramphenicol, and TMP-SMZ were essentially comparable in the United States and Canada. Vancomycin resistance was highly resistant strains when high-dose penicillin was used for treatment [29] . The same was true of a second patient populanot observed. Rifampin and the combination quinupristin/dalfopristin were nearly uniformly active in both the United States tion, treated with high-dose cefotaxime [29] . It has been inferred from these observations that in vitro and Canada.
Among the non-b-lactam antimicrobial agents examined in definitions of resistance are not relevant to the management of pneumococcal pneumonia. It should be emphasized, however, this study, rates of resistance to the macrolides, clindamycin, tetracycline, chloramphenicol, and TMP-SMZ were highest that the patients in this study received unusually high doses of penicillin or cefotaxime for management. Furthermore, baseamong strains of S. pneumoniae that were penicillin-resistant. For example, overall rates of erythromycin resistance among line rates of mortality in this study, even among patients in- the likelihood of a given therapeutic outcome.
The results of the current SENTRY surveillance study indicate that the problem of antimicrobial resistance with S. pneu-
